The turnover from the flu vaccine company of CSL fell sharply in the first half of the financial year amid a significant fall in the immunization rate, in particular in the US.
CSL Seqirus yielded a turnover of $ US1.66 billion ($ 2.6 billion) in the six months to December 31, nine percent compared to a year ago.
The turnover of its fluad-based flu shot fell by 17 percent to $ US829 million ($ 1.3 billion), while selling its cells-based flu vaccine on cells, Flucelvax, fell by 12 percent to $ 468 million ($ 745 million ).
“CSL -SQirus was negatively influenced by considerably low flu immunization percentages, in particular in the United States,” said CSL Chief Executive and director Dr. Paul McKenzie.
The American Centers for Disease Control and Prevention said in September that flu vaccine recording in the US had slowly increased before the COVID-19 Pandemie, but since then fell to the lowest level in 12 flu seasons for children and six seasons for adults.
CSL Behring, which makes blood derived from blood for people with rare diseases, did much better, with a turnover of 10 percent to $ US5.7 billion ($ 9 billion).
CSL has credited a strong demand for its immunoglobulin products and accelerated admission to his new gene therapy product to the Blood Stolling Disorder Haemophilia B.
CSL Vifor, CSL's Iron Deficiency Business, saw sales increase six percent to $ 1.08 billion.
A decrease in immunization percentages has influenced the turnover for the flu vaccine company of CSL
In general, CSL recorded the first half of $ US8.48 billion ($ 13.5 billion), an increase of five percent compared to a year ago in adjusting currency fluctuations.
It earned $ US2.07 billion ($ 3.3 billion) in net profit after tax, an increase of five percent based on constant currency.
“CSL yielded a solid result for the first half of the financial year 2025 led by CSL Behring,” Dr. McKenzie.
At 10.22 hours, CSL shares rose by 0.3 percent to $ 271.03.
